Cardiac Ablation

Cardiac Ablation

Global Cardiac Ablation Market to Reach US$2.6 Billion by 2030

The global market for Cardiac Ablation estimated at US$1.3 Billion in the year 2023, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 10.7% over the analysis period 2023-2030. Radiofrequency (RF) Ablation Technology, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Electrical Ablation Technology segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$580.2 Million While China is Forecast to Grow at 15.1% CAGR

The Cardiac Ablation market in the U.S. is estimated at US$580.2 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$196.5 Million by the year 2030 trailing a CAGR of 15.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.2% and 9.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.

Global Cardiac Ablation Market - Key Trends & Drivers Summarized

Cardiac ablation is a medical procedure used to treat arrhythmias, which are problems related to the rate or rhythm of the heartbeat. During cardiac ablation, doctors use catheters—thin, flexible tubes—to deliver energy in the form of heat (radiofrequency ablation) or extreme cold (cryoablation) to precise areas of the heart muscle. This energy destroys small sections of tissue that are causing abnormal electrical signals to disrupt the normal heart rhythm. Cardiac ablation is typically used when medications are not effective in treating the arrhythmia or cause unacceptable side effects. It is most commonly used to treat atrial fibrillation, the most common type of serious arrhythmia, but it is also employed for treating other rhythm disorders such as atrial flutter and ventricular tachycardia. The procedure is considered safe and has a high success rate, often resulting in significant improvement in quality of life for patients who suffer from frequent and severe arrhythmias.

The effectiveness and safety of cardiac ablation procedures have improved significantly with advancements in medical technology. Mapping technologies, which create detailed images of the heart`s electrical activity, have become particularly important. These technologies help physicians to precisely target the areas that need to be ablated, thereby reducing the risk of damaging non-targeted heart tissue and improving the outcomes of the procedures. Additionally, the development of robotic-assisted and magnetic navigation systems has refined the way catheters are maneuvered through the heart, enhancing the precision of the procedure and reducing its invasiveness. Moreover, the procedure has evolved to include more sophisticated approaches such as hybrid ablation, which combines surgical and catheter-based techniques for more complex arrhythmias that may be difficult to manage with a single approach. These technological advances are accompanied by ongoing research into the underlying causes of arrhythmias and the long-term effects of ablation therapy, which continuously informs and improves clinical practices.

The growth in the cardiac ablation market is driven by several factors, including the rising prevalence of cardiac arrhythmias, advancements in ablation technology, and increasing awareness and preference for minimally invasive procedures among patients and healthcare providers. As populations age globally, the incidence of arrhythmias such as atrial fibrillation naturally increases, creating a larger demand for effective treatment options like ablation. Technological innovations that enhance the safety and efficacy of these procedures also make them more attractive to both patients and physicians. For instance, the integration of real-time imaging and 3D mapping systems has significantly improved the precision of ablation procedures, reducing procedural risks and recovery times, which in turn boosts their adoption. Additionally, healthcare systems are increasingly focusing on cost-effective treatments that offer high-quality patient outcomes, and cardiac ablation often meets these criteria by reducing the long-term need for medications and their associated costs and side effects. Moreover, patient preferences are shifting towards treatments that offer quicker recovery and less post-operative discomfort, further bolstering the market for cardiac ablation solutions. Together, these factors ensure sustained growth and development in the cardiac ablation market, reflecting its critical role in contemporary cardiac care.

Select Competitors (Total 16 Featured) -

• Abbott Laboratories, Inc.
• Toray Industries, Inc.
• Boston Scientific Corporation
• Medtronic PLC
• Biotronik SE & Co. KG
• Biosense Webster, Inc.
• AtriCure, Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.